News
Rna Diagnostics, Precision Diagnostics Company, Secures CDN $8 Million in Series A Financing
TORONTO, CANADA -- (September 9, 2021) Rna Diagnostics Inc., a leading precision cancer diagnostics company, announced the closing of a CDN $8.0 M series A financing led by iGan Partners and BDC Capital, through its Bridge Financing Program. “The continued support of...
Rna Diagnostics Announces $5M Series A Financing Round Led by iGAN Partners
Rna Diagnostics Inc., a Canadian company with a patented platform technology providing real-time cancer therapy guidance, announced today the closing of a $5 million Series A financing. The funding was led by iGAN Partners and includes new and existing investors. Rna...
Rna Diagnostics Aims for 2020 Clinical Launch of Breast Cancer Treatment Guidance Test
NEW YORK (GenomeWeb) Rna Diagnostics, a Canadian molecular diagnostics company, recently commenced a clinical trial to validate an assay it plans to commercialize that can be used to guide breast cancer treatment. The trial, called Breast Cancer Response Evaluation...
First patient enrolled in BREVITY, Rna Diagnostics’ International Validation Trial of RDA™ in Primary Breast Cancer
Rna Diagnostics Inc., a Canadian company with a patented platform technology providing real-time cancer therapy guidance, announced enrollment of the first patient in the BREVITY trial at the Azienda Socio-Sanitaria Territoriale di Cremona in Cremona, Italy today....
Rna Diagnostics Inc. appoints Dr. Matthew P. Goetz to Clinical Advisory Board
Rna Diagnostics Inc. announced today that Dr. Matthew P. Goetz, Consultant and Professor at Mayo Clinic, Rochester, MN has been appointed to the company’s Clinical Advisory Board (CAB). “Dr. Goetz brings a wealth of scientific knowledge and clinical trial experience...
Rna Diagnostics Launches BREVITY – International Validation Trial of RDA™ in Breast Cancer
Rna Diagnostics announced the launch of an international prospective clinical trial to validate the RNA Disruption Assay™ (RDA™) as a tool for treatment management of primary breast cancer. BREVITY (Breast Cancer Response EValuation for Individualized TherapY) will...